Published in J Card Fail on November 01, 2007
Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol (2008) 1.69
Mechanisms by which exercise training benefits patients with heart failure. Nat Rev Cardiol (2009) 1.11
Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int (2014) 1.03
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol Med (2012) 0.96
Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol Ther (2010) 0.95
Exercise-induced Signals for Vascular Endothelial Adaptations: Implications for Cardiovascular Disease. Curr Cardiovasc Risk Rep (2012) 0.95
Acute and chronic effects of exercise on circulating endothelial progenitor cells in healthy and diseased patients. Clin Res Cardiol (2012) 0.91
Relationship between circulating progenitor cells, vascular function and oxidative stress with long-term training and short-term detraining in older men. Clin Sci (Lond) (2010) 0.89
Unraveling new mechanisms of exercise intolerance in chronic heart failure: role of exercise training. Heart Fail Rev (2013) 0.86
Functional electrical stimulation of lower limbs in patients with chronic heart failure. Heart Fail Rev (2010) 0.86
Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration. Stem Cells Int (2016) 0.84
Vascular Ageing and Exercise: Focus on Cellular Reparative Processes. Oxid Med Cell Longev (2015) 0.83
Circulating endothelial and progenitor cells: Evidence from acute and long-term exercise effects. World J Cardiol (2012) 0.82
The effect of acute exercise on endothelial progenitor cells is attenuated in chronic heart failure. Eur J Appl Physiol (2011) 0.81
Sprint interval and sprint continuous training increases circulating CD34+ cells and cardio-respiratory fitness in young healthy women. PLoS One (2014) 0.77
Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. J Gerontol A Biol Sci Med Sci (2015) 0.77
Physical exercise-induced protection on ischemic cardiovascular and cerebrovascular diseases. Int J Clin Exp Med (2015) 0.75
Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside. Biologics (2008) 0.75
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res (2004) 8.41
Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med (2014) 7.07
A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy. Eur J Anaesthesiol (2012) 4.73
Fate tracing reveals the endothelial origin of hematopoietic stem cells. Cell Stem Cell (2008) 4.17
Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev (2004) 4.12
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med (2007) 4.10
Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol (2006) 3.95
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med (2009) 3.60
Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev (2003) 3.48
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A (2004) 3.40
Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA (2009) 3.35
SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev (2007) 3.34
Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol (2008) 3.22
Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol (2008) 3.15
The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell (2009) 3.08
Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol (2003) 2.92
Sox18 induces development of the lymphatic vasculature in mice. Nature (2008) 2.91
Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med (2010) 2.88
The conditional inactivation of the beta-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J Cell Biol (2003) 2.77
EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature (2013) 2.70
The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol (2007) 2.69
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol (2004) 2.57
Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol (2006) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett (2005) 2.45
p120-Catenin regulates clathrin-dependent endocytosis of VE-cadherin. Mol Biol Cell (2005) 2.37
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A (2003) 2.28
Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2008) 2.18
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol (2008) 2.17
Endothelial cell activation leads to neutrophil transmigration as supported by the sequential roles of ICAM-2, JAM-A, and PECAM-1. Blood (2009) 2.10
VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc Natl Acad Sci U S A (2002) 2.08
The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev Cell (2010) 2.01
Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood (2008) 2.00
Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. J Mol Cell Cardiol (2006) 1.99
VE-cadherin regulates endothelial actin activating Rac and increasing membrane association of Tiam. Mol Biol Cell (2002) 1.97
C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation (2005) 1.92
VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood (2004) 1.81
Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis (2008) 1.79
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet (2002) 1.79
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail (2010) 1.78
Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun (2012) 1.78
Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration. J Cell Sci (2008) 1.74
VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell (2013) 1.73
Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail (2012) 1.73
CCM1 regulates vascular-lumen organization by inducing endothelial polarity. J Cell Sci (2010) 1.68
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail (2008) 1.65
Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol (2007) 1.64
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J (2009) 1.63
Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology (2008) 1.62
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Sox18 and Sox7 play redundant roles in vascular development. Blood (2007) 1.60
Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J (2006) 1.59
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol (2002) 1.58
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation (2003) 1.58
Postresuscitation treatment with argon improves early neurological recovery in a porcine model of cardiac arrest. Shock (2014) 1.56
Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest (2009) 1.56
Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med (2005) 1.56
Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol (2011) 1.55
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol (2006) 1.54
Sequential N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin Measurements During Albumin Replacement in Patients With Severe Sepsis or Septic Shock. Crit Care Med (2016) 1.53
Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail (2004) 1.53
Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy. Eur J Heart Fail (2013) 1.48
Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem (2005) 1.47
JAM-A mediates neutrophil transmigration in a stimulus-specific manner in vivo: evidence for sequential roles for JAM-A and PECAM-1 in neutrophil transmigration. Blood (2007) 1.47
Increased DC trafficking to lymph nodes and contact hypersensitivity in junctional adhesion molecule-A-deficient mice. J Clin Invest (2004) 1.47
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J (2005) 1.46
A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood (2002) 1.45
Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res (2002) 1.45
Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis (2007) 1.44
The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissues. J Leukoc Biol (2006) 1.42
Competitive sport after coronary angioplasty: suggested eligibility criteria for moderate-high intensity sport. J Cardiovasc Med (Hagerstown) (2008) 1.40
Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol (2004) 1.40
Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis (2003) 1.36
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation (2011) 1.35
Endothelial cell migration directs testis cord formation. Dev Biol (2008) 1.35
The multiple languages of endothelial cell-to-cell communication. Arterioscler Thromb Vasc Biol (2006) 1.33
Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and heart ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2005) 1.33
Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care (2007) 1.29
VE-Cadherin-mediated cell-cell interaction suppresses sprouting via signaling to MLC2 phosphorylation. Curr Biol (2009) 1.29
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.28
Stable vascular connections and remodeling require full expression of VE-cadherin in zebrafish embryos. PLoS One (2009) 1.28
Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care (2014) 1.27
Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. Arterioscler Thromb Vasc Biol (2008) 1.27